



Certificate No. 16909
AN ISO 9001, ISO 14001, ISO 45001
Certified Company

CIN: L24100GJ2015PLC081941



DHARMAJ[®]
CROP GUARD LIMITED

Limitless
GROWTH

August 08, 2023

To,

BSE Limited Corporate Relationship Department. PJ Towers, 25th Floor, Dalal Street, Mumbai- 400 001	National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G-Block Bandra Kurla Complex, Bandra (East), Mumbai- 400 051.
BSE Scrip Code No. 543687	NSE Symbol:-DHARMAJ

Dear Sir/Madam,

Sub: Newspaper Advertisements – 09th Annual General Meeting through Video Conferencing / Other Audio-Visual Means (“VC / OAVM”) facility.

Please find enclosed herewith copies of newspaper advertisements published in the Financial Express (English) and Financial Express (Gujarati) on 07th August, 2023, both newspapers having electronic editions, in terms of Ministry of Corporate Affairs Circulars dated 8th April, 2020, 13th April, 2020, 5th May, 2020, 13th January, 2021, 14th December, 2021, 5th May, 2022 and 28th December, 2022, inter alia, intimating that **09th Annual General Meeting of the Company will be held on Monday, 04th September, 2023 at 11:30 a.m. through VC / Other Audio Visual Means.**

The same is also available on the website of the Company www.dharmajcrop.com

Request you to kindly take the same on record.

Thanking you,

For, **Dharmaj Crop Guard Limited**

Malvika Bhadreshbhai Kapasi
Company Secretary & Compliance Officer
A52602

Regd. Office/ Factory Unit-I : Plot No. 408 to 411, Kerala GIDC Estate, Off NH-8, At : Kerala, Ta.: Bavla, Dist.: Ahmedabad- 382220, Gujarat, India. Tel.: 02714-268000

Factory Unit-II : Plot No. DP-154, GIDC-Chemical Zone, Saykha-II, Ta.- Vagra, Dist.- Bharuch – 392140, Gujarat, India.

Corporate Office: Office No. 901 to 903 & 911, B Square 2, Iscon Ambli Road, Ahmedabad- 380058, Gujarat, India. Tel.: 079-29603735 • 02717438189

Email: info@dharmajcrop.com • Web: www.dharmajcrop.com

Burgers outdo pizzas in sales of fast foods

VIVEAT SUSAN PINTO
Mumbai, August 6

DISCRETIONARY CATEGORIES SUCH as fast-food may be feeling the slowdown blues amid food inflationary pressures, but one sub-segment appears to be bucking the trend for now.

Burger sales have outperformed pizza sales for the last few quarters, visible in the same-store sales (SSG) growth numbers of players such as Westlife Foodworld and Jubilant FoodWorks (see chart). The trend is expected to stay for some time as food inflationary pressures remain and consumers increasingly get value-conscious amid a curtailment in non-essential expenditure.


Westlife runs McDonald's stores in the west and south of India; Jubilant FoodWorks is the master franchisee of Domino's Pizza in India, Bangladesh, Sri Lanka and Nepal.

Experts attribute the trend to the perception of burgers as driving individual consumption versus pizzas which tend to drive group consumption. Most burger chains such as McDonald's and Burger King have also pushed combo meals aggressively, positioning them as value-for-money, teaming burgers with french fries, a drink or any other product. This gives a filling experience to the consumer.

A combo meal could come for as low as ₹150-200 (₹179 for McSaver meals at McDonald's, for instance), going up (in terms of price) depending on what a consumer adds to his or her order. Pizzas, in contrast,

QSR MARKET SIZE IN INDIA

Quick-service restaurants



Growth rate (per annum, %)




Burgers v/s pizza: Share within QSR market (%)




*stands for Estimate

Burger v/s Pizza: Same-store sales growth of top players (%)



Growth rate (per annum, %)



Source: Industry/Company/Dolat Capital

will vary in terms of size and topping. A regular-sized veg pizza, for instance, is priced at ₹99 by Jubilant FoodWorks, though it has dropped the price in recent months to ₹49-69 under its Pizza Mania offer.

"During inflationary times, consumers take note of every little advantage and disadvantage," says Sachin Bobade, vice-president, research at brokerage firm Dolat Capital. "Burgers tend to give an in-fill experience that pizzas don't. Pizzas are also great for family occasions or when friends are meeting over. Burgers can be consumed anytime, anywhere. You don't need a group. These attributes work in its favour," he says.

A look at the fast-food market in India shows that burgers and sandwiches as a category constitute 31% of the quick-service restaurant (QSR) segment, while pizzas make up around 28%, according to industry estimates. While the gap is not huge, the growth rate is higher (19-22%) than pizzas (13-18%), experts say.

"The opportunity for all-day, individual consumption is bigger in my view than consumption of comfort food such as pizzas in groups. Which could explain why this divergence in burgers and pizza sales is showing up," Harminder Sahni, founder and MD at Gurugram-based Wazir Advisors, says.

EXPLAINER

RISING DENGUE CASES & ITS SEVERITY

In the nation's capital, dengue cases are at a five-year high, and neighbouring states are also reporting a surge. Waterlogging in several areas caused by recent heavy rainfall in the Delhi-NCR region has played a role. Also, a variant of the virus that causes a severe form of the disease has been spreading. **Sarthak Ray** analyses the Delhi dengue scenario and the state of vaccine research.



What is being done to avoid spread

The waterlogging because of heavy rainfall in the national capital region over the past few weeks allowed mosquitoes to breed and is behind the sudden spurt in dengue cases in Delhi. This was exacerbated, as reported in the media, by the strike by mosquito-control staff. The last time DENV 2 was the dominant strain in infections in the national capital—in 2015—(long with DENV 4 (another severe strain), the city saw one of the worst dengue outbreaks in a decade. While, as per MCD data, 88,000+ notices regarding mosquito-genic conditions on premises have been issued, and prosecution has been launched in 20,000 cases—as reported by The Indian Express—unnamed senior officials of the corporation bemoaned the lack of enough domestic breeding checkers (DBC) in the national capital.

The disease

A viral disease, dengue manifests in two forms: dengue fever and dengue haemorrhagic fever (DHF), a much more severe condition that can even be fatal. The virus has four variants: DENV 1, DENV 2, DENV 3, and DENV 4. The virus is transmitted through female Aedes aegyptii mosquitoes, making the disease a vector-borne one. A. aegyptii breed mostly during the monsoon season, in stagnant water near human habitation, including in homes as the mosquito needs blood to produce eggs and its larvae grow in stagnant pools of water. A. aegyptii is diurnal, unlike most mosquitoes, and can bite during the day, well into the afternoon and even early evening.

Symptoms of dengue include sudden-onset of high fever, often with delirium, head and muscle ache, joint pain, rash, and chills, among others.

4 variants of the dengue virus: Denv 1, Denv 2, DENV 3, and DENV 4

DENV 2 causes severe form of Dengue; found in most Delhi samples recently

Dengvaxia first dengue vaccine; given only to those previously infected

'Most severe' strain in samples

The Delhi government and the Municipal Corporation are mounting anti-dengue efforts on a war-footing after it emerged from serotyping of samples collected from patients in the national capital that most contained the DENV 2 variant that is widely held to be the 'most severe' because it causes Dengue Haemorrhagic Fever. DHF has a high association with mortality.

Medical experts warn to watch out for dengue shock syndrome and multiple organ failure. Dengue shock syndrome is characterised by severe plasma leakage, severe internal bleeding, impaired sensorium (a failure of general functioning of the brain, marked by confusion, loss of memory, loss of alertness, disorientation, etc), and severe organ impairment marked by elevated levels of liver enzymes, inflammation of the heart muscles, arrhythmias, etc.

Why has a vaccine evaded us

Staying protected against the disease in an endemic transmission area is virtually impossible. Thus, a vaccine is key to protection—and desperately needed by nearly half the world. But both a reliable treatment and a vaccine continue to elude dengue management.

The world's first dengue vaccine, Dengvaxia (developed by

Sanofi Pasteur), was approved by Mexico, a dengue-endemic nation, in 2015. It was welcomed with much enthusiasm. But by 2017, after 11 countries had approved it, researchers and medical officials began articulating concerns about its safety among those who had never previously suffered a dengue infection.

Dengue curiously uses the body's own immune system in the way it infects cells. While most viral infections/vaccines produce antibodies that fight off subsequent infections, the dengue virus has the ability to use antibodies to reach and enter healthy cells. Experts believe the antibodies generated by the

vaccine amplified first-time infections by making them similar to reinfection, which tend to be more severe. Sanofi, in 2017, said the vaccine should only be given to people who had suffered a prior infection. Five other candidates, including one by the Japanese giant Takeda, are in various stages of development and approval.

DHARMAJ CROP GUARD LIMITED

Regd. Office - Plot No. 408 to 411, Kerala GIDC Estate, Off NH-8, At : Kerala, Ta : Bavia, Ahmedabad- 382220.
website: www.dharmajcrop.com, email: info@dharmajcrop.com, CIN: L24100GJ2015PLC081941

PUBLIC NOTICE

NOTICE is hereby given that the 99th Annual General Meeting ("AGM") of Dharmaj Crop Guard Limited will be held on Monday, 04th day of September, 2023 at 11.30 a.m. through Video Conference (VC) / Other Audio Visual Means (OAVM), in compliance with the circulars issued by Ministry of Corporate Affairs (MCA) and SEBI and all other relevant circulars issued from time to time.

The Company is pleased to provide the facility of attending the meeting through VC / OAVM to the members of the Company and facility of voting during the meeting through electronic means in compliance of the above stated circulars. The members holding shares as on the cut-off date (i.e. 28.08.2023) including those who have not received the electronic copy of the Annual report of the Company due to non-availability of e-mail ID with the Company / RTA can also exercise their vote by following the instructions given in the Notice of AGM.

In accordance with the above circulars, the Company will send in due course the Annual Report of the Company for the financial year 2022-23 including the Notice of Annual General Meeting by way of an e-mail to those members whose e-mail ID are registered with the Company / RTA. So those members who have not registered their e-mail ID are requested to get the same registered. Member holding shares in Demat mode are requested to contact their respective Depository Participant for registering the email addresses.

The notice of the Annual General Meeting of the Company will also be made available on the Company's website at www.dharmajcrop.com and the Stock Exchanges Website i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.

For Dharmaj Crop Guard Limited

Date : August 05, 2023

Malvika Bhadreshbhai Kapasi
Company secretary and Compliance Officer
AS2602



BHAGERIA INDUSTRIES LIMITED

(CIN : L40300MH1989PLC052574)
Regd. Office: 1002, 10th Floor, Topiwala Centre, Off S.V. Road, Goregaon (W), Mumbai 400 062. Phone: +91-22-4043 6666, Fax: +91-22-4043 6662, Email id: info@bhageriagroup.com Website: www.bhageriagroup.com

EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(Rs. in lakhs (Except figures of EPS)

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		30-06-2023	31-03-2023	30-06-2022	31-03-2023	30-06-2023	31-03-2023	30-06-2022	31-03-2023
1	Total Income from operations (net)	10,105.41	14,523.30	10,855.78	50,509.81	10,105.48	14,523.45	10,859.64	50,533.49
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	145.93	766.00	273.22	2,071.43	141.27	763.27	268.67	2,036.80
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	145.93	766.00	273.22	2,071.43	141.27	763.27	268.67	2,036.80
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	129.11	500.44	241.15	1,504.81	124.45	497.71	237.73	1,471.02
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	131.16	497.53	241.86	1,513.03	126.51	494.80	238.43	1,479.24
6	Equity Share Capital	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21
7	Reserve (excluding revaluation reserve as shown in the Balance Sheet of Previous Year)	-	-	-	48,259.07	-	-	-	48,430.79
8	Earning Per Share (Face Value of Rs.5/- each) (Not to be annualized)								
	1. Basic :	0.30	1.15	0.55	3.45	0.29	1.14	0.54	3.38
	2. Diluted :	0.30	1.15	0.55	3.45	0.29	1.14	0.54	3.38

Notes:

- The Unaudited Financial Result for the quarter ended 30th June, 2023 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at the meeting held on 05th Aug, 2023. The Statutory Auditors of the Company have carried out "Limited Review" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- The figures for the quarters ended on 31st March, 2023 are the balancing figures between audited figures for the full financial year and published year to date figures up to the third quarter of the respective financial year.
- The above is an extract of the detailed format of Quarterly Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchanges website (www.bseindia.com and www.nseindia.com) and on Company's website (www.bhageriagroup.com).

For Bhageria Industries Limited

Place : Mumbai

Date : 05.08.2023

Vinod Bhageria
Managing Director
DIN : 00540308



Investment Manager: Baroda BNP Paribas Asset Management India Private Limited (AMC)
Corporate Identity Number (CIN): U65991MH2003PTC142972

Registered Office: Crescenzo, 7th Floor, G-Block, Bandra Kurla Complex, Bandra - East, Mumbai - 400 051.
Website: www.barodabnpbbasmf.in • Toll Free: 18002670189

NOTICE NO. 40/2023

Declaration of Income Distribution cum Capital Withdrawal (IDCW) under the designated Scheme of Baroda BNP Paribas Mutual Fund (the Fund):

Notice is hereby given to all the unitholders of Baroda BNP Paribas Arbitrage Fund ("Scheme"), that following shall be the rate of distribution under Income Distribution cum Capital Withdrawal ("IDCW") Options of respective plan under the Scheme with **Wednesday, August 09, 2023** as the Record Date:

Name of the Scheme	Name of Plans/ Options	NAV per unit as on August 03, 2023 (face value per unit of ₹ 10/-)	Distribution per unit** (In ₹)
Baroda BNP Paribas Arbitrage Fund	Regular Plan - Monthly IDCW Option	10.2735	0.05
	Direct Plan - Monthly IDCW Option	10.5934	0.05

*or the immediately following Business Day, if that day is not a Business Day.

The distribution will be subject to the availability of distributable surplus and may be lower, depending on the distributable surplus available on the Record Date.

**Net distribution amount will be paid to the unit holders under respective categories after deducting applicable taxes, if any.

For the units held in physical form, amount of distribution will be paid to all unit holders whose names appear in the records of the Registrar at the close of business hours on the record date and for units held in demat form, the names appearing in the beneficial owners master with the Depository as on the record date shall be considered.

Pursuant to distribution under IDCW, NAV of the IDCW option of the scheme(s) would fall to the extent of payout and statutory levy (if applicable).

For Baroda BNP Paribas Asset Management India Private Limited
(Formerly BNP Paribas Asset Management India Private Limited)
(Investment Manager to Baroda BNP Paribas Mutual Fund)

Sd/-
Authorised Signatory

Date : August 04, 2023
Place : Mumbai

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS,
READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.



AARTI PHARMALABS LIMITED

(Formerly known as Aarti Organics Limited)

CIN: L24100GJ2019PLC110964

Registered Office: Plot No. 22/C/1 & 22/C/2, 1st Phase, GIDC Vapi- 396195, Valsad, Gujarat.
Corporate Office: 204, Udyog Kshetra, 2nd Floor, Mulund Goregaon Link Road, Mulund West, Mumbai- 400080, Maharashtra
Website: www.aarti-pharmalabs.com; Email: investorrelations@aarti-pharmalabs.com

Extract of Audited Financial Results for the quarter ended June 30, 2023

(₹ In Lakhs except for Share data)

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
1	Total Income from Operations (Net)	36,300	37,427	37,315	1,51,253	45,884	48,580	45,739	1,94,755
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	6,213	5,674	6,225	23,336	6,398	5,884	6,806	26,077
3	Exceptional items	0	0	0	0	0	0	0	0
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	4,763	3,999	4,725	17,173	4,709	4,287	5,184	19,349
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	117	-63	-28	-70	388	-505	-28	-345
6	Total Comprehensive Income for the period	4,880	3,937	4,698	17,103	5,097	3,782	5,156	19,004
7	Paid-up Equity Share Capital (Face Value of Rs. 5/- each)	4,531	4,531	4,556	4,531	4,531	4,531	4,556	4,531
8	Reserves (excluding Revaluation Reserve)	-	-	-	1,39,327	-	-	-	1,51,317
9	Net Worth	-	-	-	1,43,858	-	-	-	1,55,849
10	Earnings Per Share (of Rs. 5/- each) (for continuing and discontinued operations)								
	1. Basic:	5.26	4.41	5.21	18.95	5.20	4.73	5.72	21.35
	2. Diluted:	5.26	4.41	5.21	18.95	5.20	4.73	5.72	21.35

Notes:-

- The above is an extract of the detailed format of Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the websites of Stock Exchange(s) viz. www.bseindia.com and www.nseindia.com and website of the Company i.e. www.aarti-pharmalabs.com
- The above results for the quarter ended June 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on August 5, 2023
- The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The Company has identified only one segment i.e. Pharmaceuticals as reporting segment

Place: Mumbai
Date: August 5, 2023

For AARTI PHARMALABS LIMITED
Sd/-
Hetal Gogri Gala
Vice Chairperson & Managing Director
DIN: 00005499

